Cover Image
市場調查報告書

中國的診斷劑產業報告

China Diagnostic Reagent Industry Report, 2013-2016

出版商 ResearchInChina 商品編碼 289195
出版日期 內容資訊 英文 140 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的診斷劑產業報告 China Diagnostic Reagent Industry Report, 2013-2016
出版日期: 2014年07月29日 內容資訊: 英文 140 Pages
簡介

2012年,中國的診斷劑市場規模,與去年比較增加16.7%,達133億人民幣。2008年∼2012年的CAGR達15%的成長。

本報告提供中國的診斷劑產業調查分析、產業概要、現狀、發展趨勢相關驗證,再加上主要企業簡介,為您概述為以下內容。

第1章 診斷劑產業概要

  • 定義
  • 分類
  • 產業鏈

第2章 中國的診斷劑產業現狀

  • 概要
  • 市場結構
  • 進出口
  • 競爭格局
  • 市場區隔
    • 生物化學診斷劑
    • 免疫診斷試劑
    • 分子診斷試劑
    • 整合體外診斷劑

第3章 中國的診斷劑產業的開發環境與趨勢

  • 積極的因素
  • 趨勢

第4章 中國的主要診斷劑企業

  • Shanghai Kehua Bio-engineering Co., Ltd.
  • Beijing Strong Biotechnologies, Inc (BSBE)
  • Da An Gene Co., Ltd.
  • Fosun Pharmaceutical (Group) Co., Ltd.
  • BioSino Bio-technology and Science Inc.
  • Beijing Kinghawk Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Beijing Leadman Biochemistry Co., Ltd.
  • Changsha Sinocare Inc.
  • Bohui Innovation Technology Co., Ltd.
  • 其他

第5章 彙整與預測

  • 中國的診斷劑產業的預測和概況
  • 主要企業的業績比較
  • 收益
  • 淨利
  • 毛利
  • 體外診斷商務

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: ZLC-006

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic reagent industry has been developing quickly, especially in vitro diagnostic reagents occupy over 90%. In 2013, Chinese in vitro diagnostics market size reached RMB22.98 billion, of which RMB16.61 billion came from in vitro diagnostic reagents.

Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013.

Currently, about 40%-50% share of the Chinese in vitro diagnostics market has been dominated by foreign companies represented by Roche, Siemens, Abbott and Johnson & Johnson. Although there are 300-400 local enterprises in China in vitro diagnostics industry, the top ten Chinese companies which rank by production scale only seize 30% market share, reflecting a low industry concentration degree.

Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.

In 2014, a number of local Chinese diagnostic reagent companies (including BSBE, Maker Biotechnology, Health BioMed, Wondfo, Thalys) intend to step in the capital market through IPO because they are optimistic about the prospects of the diagnostic reagent industry; the raised funds will be used in the expansion of the existing projects or the construction of new projects. SHINVA, Humanwell Healthcare and Zhongyuan Union Stem Cell Bioengineering have entered the diagnostic reagent industry through acquisitions.

image1

The report covers the following:

  • Status quo of China diagnostic reagent industry, including overview, market structure, import, export, competition pattern and so on;
  • Development environments and trends of China diagnostic reagent industry, embracing macroeconomy, medical situation, and relevant policies;
  • Operation and diagnostic reagent business of 17 major companies in China diagnostic reagent industry.

Table of Contents

1 Overview of Diagnostic Reagent Industry

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 Industry Chain

2 Status Quo of China Diagnostic Reagent Industry

  • 2.1 Overview
  • 2.2 Market Structure
  • 2.3 Import and Export
    • 2.3.1 Import
    • 2.3.2 Export
  • 2.4 Competition Pattern
  • 2.5 Market Segments
    • 2.5.1 Biochemical Diagnostic Reagents
    • 2.5.2 Immunodiagnostic Reagents
    • 2.5.3 Molecular Diagnostic Reagents
    • 2.5.4 Comprehensive In Vitro Diagnostic Reagents

3 Development Environments and Trends of China Diagnostic Reagent Industry

  • 3.1 Positive Factors
    • 3.1.1 Macroeconomy
    • 3.1.2 Medical Care
    • 3.1.3 Policies
  • 3.2 Trends
    • 3.2.1 Biochemical Immunodiagnostics is still the Mainstream
    • 3.2.2 High Industrial Concentration Degree
    • 3.2.3 Integrated Enterprises will See Better Development

4 Major Enterprises

  • 4.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 R & D and Investment
    • 4.1.6 Supply and Marketing
    • 4.1.7 In Vitro Diagnostics Business
    • 4.1.8 Anticipation and Outlook
  • 4.2 Beijing Strong Biotechnologies, Inc (BSBE)
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R & D and Investment
    • 4.2.6 Production and Marketing
    • 4.2.7 Supply and Marketing
    • 4.2.8 Anticipation and Outlook
  • 4.3 Da An Gene
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R & D and Investment
    • 4.3.6 Diagnostic Reagent Business
    • 4.3.7 Supply and Marketing
    • 4.3.8 Anticipation and Outlook
  • 4.4 Fosun Pharmaceutical
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R & D and Investment
    • 4.4.6 Diagnostic Reagent Business
    • 4.4.7 Anticipation and Outlook
  • 4.5 Beijing Leadman Biochemistry Co., Ltd.
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 R & D and Investment
    • 4.5.6 Clients
    • 4.5.7 Anticipation and Outlook
  • 4.6 Livzon Pharmaceutical Group Inc.
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R & D
    • 4.6.6 Diagnostic Reagent Business
    • 4.6.7 Anticipation and Outlook
  • 4.7 Mindray Medical
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R & D and Investment
    • 4.7.6 Diagnostic Reagent Business
    • 4.7.7 Anticipation and Outlook
  • 4.8 Biosino Bio-Technology & Science Inc.
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 Anticipation and Outlook
  • 4.9 Maker Biotechnology
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Revenue Structure
    • 4.9.4 Gross Margin
    • 4.9.5 R & D and Investment
    • 4.9.6 Supply and Marketing
    • 4.9.7 Production and Marketing
    • 4.9.8 Anticipation and Outlook
  • 4.10 Sinocare
    • 4.10.1 Profile
    • 4.10.2 Operation
    • 4.10.3 Revenue Structure
    • 4.10.4 Gross Margin
    • 4.10.5 Anticipation and Outlook
  • 4.11 Beijing Kinghawk Pharmaceutical Co., Ltd.
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Revenue Structure
    • 4.11.4 Gross Margin
    • 4.11.5 Anticipation and Outlook
  • 4.12 Bohui Innovation
    • 4.12.1 Profile
    • 4.12.2 Operation
    • 4.12.3 Revenue Structure
    • 4.12.4 Gross Margin
    • 4.12.5 R & D and Investment
    • 4.12.6 Anticipation and Outlook
  • 4.13 Health BioMed
    • 4.13.1 Profile
    • 4.13.2 Operation
    • 4.13.3 Revenue Structure
    • 4.13.4 Gross Margin
    • 4.13.5 Supply and Marketing
    • 4.13.6 R & D and Investment
    • 4.13.7 Anticipation and Outlook
  • 4.14 Wondfo
    • 4.14.1 Profile
    • 4.14.2 Operation
    • 4.14.3 Revenue Structure
    • 4.14.4 Gross Margin
    • 4.14.5 Supply and Marketing
    • 4.14.6 R & D and Investment
    • 4.14.7 Anticipation and Outlook
  • 4.15 Thalys
    • 4.15.1 Profile
    • 4.15.2 Operation
    • 4.15.3 Revenue Structure
    • 4.15.4 Gross Margin
    • 4.15.5 Production and Marketing
    • 4.15.6 Supply and Marketing
    • 4.15.7 R & D and Investment
    • 4.15.8 Anticipation and Outlook
  • 4.16 SHINVA
    • 4.16.1 Profile
    • 4.16.2 Operation
    • 4.16.3 Gross Margin
    • 4.16.4 Diagnostic Reagent Business
  • 4.17 Humanwell Healthcare
    • 4.17.1 Profile
    • 4.17.2 Operation
    • 4.17.3 Diagnostic Reagent Business

5 Summary and Forecast

  • 5.1 Anticipation and Outlook of China Diagnostic Reagent Industry
  • 5.2 Operation Comparison between Major Companies
    • 5.2.1 Revenue
    • 5.2.2 Net Income
    • 5.2.3 Gross Margin
    • 5.2.4 In Vitro Diagnostics Business

Selected Charts

  • Classification of In Vitro Diagnostic Reagents (by Detection Principle)
  • In Vitro Diagnostic Reagent Categories and Products (by National Policies)
  • Diagnostic Reagent Industry Chain
  • China's In Vitro Diagnostics Market Size, 2009-2013
  • China's In Vitro Diagnostic Reagent Market Structure, 2013
  • China's Diagnostic Reagent Import Volume, 2008-2013
  • China's Diagnostic Reagent Import Value, 2008-2013
  • China's Diagnostic Reagent Import Sources and Value, 2012-2013
  • China's Diagnostic Reagent Export Volume, 2008-2013
  • China's Diagnostic Reagent Export Value, 2008-2013
  • Top 10 Destinations of Chinese Diagnostic Reagents by Export Volume and Value, 2012-2013
  • Diagnostic Instrument Comparison between Domestic and Foreign Enterprises
  • Competition Pattern of China Diagnostic Reagent Industry
  • In Vitro Diagnostics Revenue and Market Share of Major Diagnostic Reagent Companies in China, 2013
  • China's GDP and YoY Growth Rate, 2004-2013
  • China's Total Population and YoY Growth Rate, 2006-2013
  • Population of 65-year-old People (or Older) and % of Total Population in China, 2004-2013
  • China's Health Expenditure and % of GDP, 1980-2013
  • China's Per Capita Health Expenditure and YoY Growth Rate, 2006-2012
  • Number of Medical Institutions In China, 2012-2013
  • Workload of Health Institutions in China, 2012-2013
  • Main Policies of China Diagnostic Reagent Industry, 2010-2013
  • Development Process of Roche Diagnostics
  • Integrated Development Strategies of Global Leading Diagnostic Reagent Companies
  • KHB's Revenue and Net Income, 2009-2013
  • KHB's Revenue (by Product), 2009-2013
  • KHB's Revenue Structure (by Product), 2009-2013
  • KHB's Revenue (by Region), 2009-2013
  • KHB's Revenue Structure (by Region), 2009-2013
  • KHB's Gross Margin, 2009-2013
  • KHB's Gross Margin (by Product), 2009-2013
  • KHB's Gross Margin (by Region), 2010-2013
  • KHB's R & D Costs and % of Total Revenue, 2011-2013
  • Key National Projects Involved with KHB
  • KHB's Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
  • Comparison between KHB's Top 5 Clinets, 2012-2013
  • Comparison between KHB's Top 5 Suppliers, 2012-2013
  • KHB's Medical Instrument Categories and Products, 2013
  • KHB's Revenue and Net Income, 2012-2016E
  • BSBE's Revenue and Net Income, 2011-2013
  • BSBE's Revenue and Structure (by Product), 2011-2013
  • BSBE's Gross Margin, 2011-2013
  • Gross Margin of BSBE's Independent Products, 2011-2013
  • Gross Margin of BSBE's Agent Products, 2011-2013
  • BSBE's R & D Costs and % of Total Revenue, 2011-2013
  • BSBE's Investment Projects and Value
  • BSBE's Capacity, Output and Sales Volume, 2011-2013
  • BSBE's Top 10 Products by Sales, 2013
  • BSBE's Top 5 Raw Material Suppliers, 2011-2013
  • BSBE's Top 5 Distributors, 2011-2013
  • BSBE's Revenue and Net Income, 2011-2016E
  • Revenue and Net Income of Da An Gene, 2009-2013
  • Revenue of Da An Gene (by Product) , 2009-2013
  • Revenue Structure of Da An Gene (by Product) , 2009-2013
  • Revenue of Da An Gene (by Region), 2009-2013
  • Revenue Structure of Da An Gene (by Product) , 2009-2013
  • Gross Margin of Da An Gene, 2009-2013
  • Gross Margin of Da An Gene (by Product), 2009-2013
  • R & D Costs and % of Total Revenue of Da An Gene, 2011-2013
  • Reagent Revenue and YoY Growth of Da An Gene, 2009-2013
  • Instrument Revenue and YoY Growth Rate of Da An Gene, 2009-2013
  • Principal Assets and Business of Da An Gene
  • Medical Resources of Sun Yat-sen University
  • Top 5 Clients of Da An Gene, 2013
  • Top 5 Clients of Da An Gene, 2012
  • Top 5 Suppliers of Da An Gene, 2013
  • Top 5 Suppliers of Da An Gene, 2012
  • Revenue and Net Income of Da An Gene, 2012-2016E
  • Revenue and Net Income of Fosun Pharmaceutical, 2009-2013
  • Revenue of Fosun Pharmaceutical (by Business), 2009-2013
  • Revenue Structure of Fosun Pharmaceutical (by Business), 2009-2013
  • Revenue of Fosun Pharmaceutical (by Region), 2009-2013
  • Revenue Structure of Fosun Pharmaceutical (by Region), 2009-2013
  • Gross Margin of Fosun Pharmaceutical, 2009-2013
  • Gross Margin of Fosun Pharmaceutical (by Business), 2009-2013
  • R & D Costs and % of Total Revenue of Fosun Pharmaceutical, 2010-2013
  • Medical Diagnosis and Medical Equipment Revenue as well as % of Total Revenue of Fosun Pharmaceutical, 2009-2013
  • Revenue and Net Income of Fosun Pharmaceutical, 2012-2016E
  • Leadman's Revenue and Net Income, 2009-2013
  • Leadman's Revenue (by Product), 2009-2013
  • Leadman's Revenue Structure (by Product), 2009-2013
  • Leadman's Gross Margin, 2009-2013
  • Leadman's Gross Margin (by Product), 2009-2013
  • Leadman's R & D Costs and% of Total Revenue, 2011-2013
  • Leadman's Top 5 Clients, 2013
  • Leadman's Top 5 Clients, 2012
  • Leadman's Revenue and Net Income, 2012-2016E
  • Livzon's Revenue and Net Income, 2009-2013
  • Livzon's Revenue (by Product), 2009-2013
  • Livzon's Revenue Structure (by Product), 2009-2013
  • Livzon's Revenue (by Region), 2009-2013
  • Livzon's Revenue Structure (by Region), 2009-2013
  • Livzon's Gross Margin, 2009-2013
  • Livzon's Gross Margin (by Product), 2009-2013
  • Livzon's Main Diagnostic Reagent Products
  • Revenue and YoY Growth Rate of Livzon's Diagnostic Reagents and Equipment, 2009-2013
  • Livzon's Revenue and Net Income, 2012-2016E
  • Revenue and Net Income of Mindray Medical, 2009-2013
  • Revenue of Mindray Medical (by Product), 2009-2013
  • Revenue Structure of Mindray Medical (by Product), 2009-2013
  • Gross Margin of Mindray Medical, 2009-2013
  • R & D Costs and % of Total Revenue of Mindray Medical, 2009-2013
  • In Vitro Diagnostic Product Revenue and YoY Growth Rate of Mindray Medical, 2009-2013
  • Revenue and Net Income of Mindray Medical, 2012-2016E
  • Biosino's Revenue and Net Income, 2009-2013
  • Biosino's Revenue (by Product), 2009-2013
  • Biosino's Revenue Structure (by Product), 2009-2013
  • Biosino's Gross Margin, 2009-2013
  • Biosino's Revenue and Net Income, 2012-2016E
  • Product Structure of Maker Biotechnology
  • Revenue and Net Income of Maker Biotechnology, 2011-2013
  • Sales and Structure of Independent Products of Maker Biotechnology, 2011-2013
  • Agent Brand Sales and Structure of Maker Biotechnology, 2011-2013
  • Sales and Structure of Maker Biotechnology (by Client), 2011-2013
  • Comparison between Direct sales and Distribution Revenue of Maker Biotechnology (by Region), 2011-2013
  • Gross Margin of Maker Biotechnology, 2011-2013
  • R & D Costs and % of Total Revenue of Maker Biotechnology, 2011-2013
  • Investment Projects and Value of Maker Biotechnology
  • Top 10 Suppliers of Maker Biotechnology, 2012-2013
  • Dealer Distribution of Maker Biotechnology, 2011-2013
  • Top 5 Clients of Maker Biotechnology, 2011-2013
  • Capacity, Output and Sales Volume of Maker Biotechnology, 2011-2013
  • Comparison between Independent Diagnostic Products and Agent Diagnostic Products of Maker Biotechnology
  • Revenue and Net Income of Maker Biotechnology, 2012-2016E
  • Sinocare's Revenue and Net Income, 2009-2013
  • Sinocare's Revenue Structure (by Product), 2009-2013
  • Sinocare's Gross Margin, 2009-2013
  • Sinocare's Gross Margin (by Product), 2009-2013
  • Sinocare's Revenue and Net Income, 2012-2016E
  • Revenue and Net Income of Kinghawk Pharmaceutical, 2009-2013
  • Revenue of Kinghawk Pharmaceutical (by Product), 2010-2012
  • Revenue Structure of Kinghawk Pharmaceutical (by Product), 2010-2012
  • Gross Margin of Kinghawk Pharmaceutical, 2009-2013
  • Gross Margin of Kinghawk Pharmaceutical (by Product), 2010-2012
  • Revenue and Net Income of Kinghawk Pharmaceutical, 2012-2016E
  • Revenue and Net Income of Bohui Innovation, 2009-2013
  • Revenue of Bohui Innovation (by Product), 2009-2013
  • Revenue Structure of Bohui Innovation (by Product), 2009-2013
  • Gross Margin of Bohui Innovation, 2009-2013
  • Gross Margin of Bohui Innovation (by Product), 2009-2013
  • R & D Costs and % of Total Revenue of Bohui Innovation, 2010-2013
  • Revenue and Net Income of Bohui Innovation, 2012-2016E
  • Revenue and Net Income of Health BioMed, 2011-2013
  • Revenue and Structure of Health BioMed (by Product), 2011-2013
  • Revenue and Structure of Health BioMed (by Region), 2011-2013
  • Revenue and Structure of Health BioMed (by Client), 2011-2013
  • Gross Margin of Health BioMed, 2011-2013
  • Gross Margin of Health BioMed (by Product), 2011-2013
  • Top 5 Suppliers of Health BioMed, 2011-2013
  • Top 5 Clients of Health BioMed, 2011-2013
  • R & D Costs and % of Total Revenue of Health BioMed, 2011-2013
  • In Vitro Diagnostic Items, Product Categories and Operation Modes of Health BioMed
  • Investment Projects and Value of Health BioMed
  • Revenue and Net Income of Health BioMed, 2011-2016E
  • Application and Detection Methods of Wondfo's Products
  • Wondfo's Revenue and Net Income, 2011-2013
  • Wondfo's Revenue (by Product), 2011-2013
  • Wondfo's Revenue Structure (by Product), 2011-2013
  • Wondfo's Revenue (by Region), 2011-2013
  • Wondfo's Gross Margin, 2011-2013
  • Wondfo's Gross Margin (by Product), 2011-2013
  • Wondfo's Top 5 Suppliers, 2011-2013
  • Wondfo's Top 5 Clients, 2011-2013
  • Wondfo's R & D Costs and % of Total Revenue, 2011-2013
  • Wondfo's Investment Projects and Purposes of Raised Funds
  • Wondfo's Revenue and Net Income, 2011-2016E
  • Revenue and Net Income of Thalys, 2011-2013
  • Revenue and Structure of Thalys (by Business), 2011-2013
  • Revenue and Structure of Thalys (by Region), 2011-2013
  • Gross Margin of Thalys, 2011-2013
  • Gross Margin of Thalys (by Business), 2011-2013
  • Capacity, Output, Sales Volume, Capacity Utilization and Sales/Output Ratio of Thalys' Independent Products, 2011-2013
  • Top 5 Clients of Thalys, 2011-2013
  • Top 5 Suppliers of Thalys, 2011-2013
  • Sales and R & D COSTS of Thalys' Independent Products, 2011-2013
  • Investment Projects and Raised Funds of Thalys
  • Revenue and Net Income of Thalys, 2011-2016E
  • SHINVA's Revenue and Net Income, 2009-2013
  • SHINVA's Gross Margin, 2009-2013
  • Revenue and Net Income of Humanwell Healthcare, 2009-2013
  • Chinese In Vitro Diagnostics Market Size, 2012-2016E
  • Revenue Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
  • Net Income Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
  • Net Profit Margin Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
  • Gross Margin Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
  • In Vitro Diagnostics Revenue Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
Back to Top